Cipla Ltd

Large Cap

Healthcare Sector

reflects a positive outlook for the share price

reflects a neutral outlook for the share price

reflects a negative outlook for the share price

The analysts information is for reference only and does not\n  represents an investment recommendation.

Analyst recommendation reflect the views of analysts who follow and write research reports.

Company Information is an introduction to the company’s business that details what it sell, how it was founded, what their mission is, how they manufacture or source their products, and why they serve customers.

Cipla's stock dropped 4% after the USFDA issued a Form 483 to Pharmathen, citing multiple compliance gaps at its facility, raising concerns over Lanreotide supply.

Cipla Shares Decline Following USFDA Compliance Issues - 07 Jan, 2026

Cipla's historical export of essential medicines to Venezuela underscores its trade exposure, while analysts also discuss opportunities amid rising generic competition in the pharma sector.

Cipla's Trade Exposure to Venezuela Highlighted - 05 Jan, 2026

Cipla has launched Afrezza, a rapid-acting inhaled insulin powder, in India, providing a convenient, needle-free alternative for diabetes management. This innovation aims to benefit millions of adults living with diabetes.

Cipla Introduces Needle-Free Inhaled Insulin for Diabetes - 22 Dec, 2025

Cipla Ltd has entered an exclusive agreement with Pfizer India to market and distribute four key pharmaceutical products, enhancing its portfolio in the Indian market.

Cipla Partners with Pfizer for Exclusive Marketing Rights - 20 Dec, 2025

Cipla Ltd has entered an exclusive agreement with Pfizer to market and distribute five key brands in India, aiming to enhance access to essential medicines. This partnership leverages Cipla's extensive distribution network and marks the first collaboration between the two companies in India.

Cipla Forms Strategic Partnership with Pfizer - 19 Dec, 2025

Cipla Limited has launched Yurpeak (Tirzepatide), a once-weekly injectable therapy for obesity and type 2 diabetes in India, enhancing access to innovative treatments.

Cipla Launches Yurpeak for Obesity and Diabetes - 10 Dec, 2025

Price to Earnings Ratio or Price to Earnings Multiple is the ratio of the share price of a stock to its earnings per share (EPS). It provides an indication of whether a stock at its current market price is expensive or cheap.

The price/earnings-to-growth ratio, or the PEG ratio, is a metric that helps investors value a stock by taking into account a company's market price, its earnings, and its future growth prospects.

Enterprise value (EV) is the total value of a company, defined in terms of its financing. It includes both the current share price (market capitalization) and the cost to pay off debt (net debt, or debt minus cash).

Alpha measures the amount that the investment has returned in comparison to the market index or other broad benchmark that it is compared against.

Beta measures a stock's volatility, the degree to which its price fluctuates in relation to the overall stock market. In other words, it gives a sense of the stock's risk compared to that of the greater market.

Dividend yield measures the quantum of earnings by way of total dividends that investors make by investing in that company.

The debt-to-total-assets ratio shows how much of a business is owned by creditors (people it has borrowed money from) compared with how much of the company's assets are owned by shareholders.

Operating cash flow (OCF) is a measure of the amount of cash generated by a company's normal business operations. Operating cash flow indicates whether a company can generate sufficient positive cash flow to maintain and grow its operations.

This widget shows the information about the stock's peers in consideration along with the different data for those peers so that the user can compare the stock with the other similar stock and invest accordingly.

Promoter holding is the amount of share of the company that is owned by the promoters. The promoters are the company's founders, who hold a majority stake in the company's capital.

A foreign institutional investor (FII) is an investor or investment fund investing in a country outside of the one in which it is registered or headquartered.

A mutual fund is a pool of money managed by a professional Fund Manager. It is a trust that collects money from a number of investors who share a common investment objective and invests the same in equities, bonds, money market instruments, and other securities.

Retail investors execute their trades through traditional or online brokerage firms or other types of investment accounts. Retail investors purchase securities for their own personal accounts and often trade in dramatically smaller amounts as compared to institutional investors.

This widget shows the bifurcation of stocks based on the percentage of stake with the different types of shareholders.

This widget will help value the stock based on the Price to Earning ratio of the stock and compare the valuation with the industry value and other similar stocks. It even shows the timeline of the valuation of the stock and its highest and lowest valuation over time.
A Time Series data is provided which compares the historical stock PE with Industry PE over the period of 5 years.

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

Revenue is up for the last 3 quarters, 7.01K Cr → 7.85K Cr (in ₹), with an average increase of 5.5% per quarter

This section gives you an insight into how the revenue of the company has moved for the last few quarters.

Revenue Rich

Netprofit is up for the last 3 quarters, 1.22K Cr → 1.35K Cr (in ₹), with an average increase of 4.9% per quarter

This section gives you an insight into how the profit for the company has been for the last few quarters.

Profit Spike

Promoters holdings remained unchanged at 29.13% of holdings in Sep 2025 quarter

This section gives you an insight into how the Promoter Holding has changed for the stock over the last few quarters.

Promoter Holding Unchanged

In the last 1 year, Torrent Pharmaceuticals Ltd has given 21.0% return, outperforming this stock by 21.3%

This section gives you an insight into how the peers have performed as compared to this company in the last 1 year.

Against Peers

In the last 3 years, Torrent Pharmaceuticals Ltd has given 153.2% return, outperforming this stock by 117.3%

This section gives you an insight into how the peers have performed as compared to this company in the last 3 years.

Retail Investor have decreased holdings from 16.26% to 15.94% in Sep 2025 quarter

This section gives you an insight into how the Retail Investors Holding has changed for the stock over last few quarters.

Retail Holding Down

Mutual Funds have decreased holdings from 20.40% to 20.17% in Sep 2025 quarter

This section gives you an insight into how the Mutual Funds Holding has changed for the stock over last few quarters.

MF Holding Down

Foreign Institutions have decreased holdings from 25.19% to 24.47% in Sep 2025 quarter

This section gives you an insight into how the FII Holding has changed for the stock over last few quarters.

FII Holding Down

In the last 1 year, CIPLA stock has moved down by -0.2%

This section gives you an insight into the price movement of the stock for the last few quarters.

Price Dip

BSE 100

S&P BSE 100 LargeCap TMC

S&P BSE SENSEX 50

BSE 200

NIFTY PHARMA

S&P BSE 100 ESG

Nifty 500

BSE MFG

BSE Healthcare

S&P BSE Dividend Stability

BSE 500

Nifty Healthcare

S&P BSE Largecap

Nifty100 Eq Weig

Nifty50 Value 20

NIFTY 100

S&P BSE 250 LargeMidCap

NIFTY 50

Nifty100 Low Volatility 30

Nifty LargeMidcap 250

Nifty 200

HDFC Flexi Cap Fund -Direct Plan - Growth Option

Parag Parikh Flexi Cap Direct Growth

SBI ELSS Tax Saver Fund Direct Growth

HDFC Focused Fund -Direct Plan - Growth Option

HDFC ELSS TaxSaver -Direct Plan - Growth Option

Cipla Ltd’s net profit jumped 3.73% since last year same period to ₹1,351.17Cr in the Q2 2025-2026. On a quarterly growth basis, Cipla Ltd has generated 4.13% jump in its net profits since last 3-months.

Name	Value	Action
MACD level (12,26)	0.36	Bullish
CCI (20)	-245.77	Bullish
RSI (14)	54.14	Neutral
Momentum (10)	0.6	Bullish
ADI (14)	25.3	Bullish
Ultimate Oscillator (7,14,28)	62.87	Neutral

Name	Value	Action
SMA (20)	1465.57	Bullish
EMA (20)	1465.63	Bullish
VWMA (20)	1465.81	Bullish
SMA (50)	1464.89	Bullish
EMA (50)	1465.15	Bullish
SMA (200)	1463.54	Bullish
EMA (200)	1463.96	Bullish
KAMA (200)	1464.38	Bullish
DEMA (200)	1465.02	Bullish

Cipla Ltd (CIPLA)

Summary

Overall

Oscillators

Moving Averages